Yang-xun Pan - Publications

FOLFOX-HAIC versus first-line systemic chemotherapy in HBsAg-positive patients with unresectable intrahepatic cholangiocarcinoma: A propensity score matched cohort study.

Journal: Hepatobiliary & pancreatic diseases international : HBPD INT

Published: December 18, 2025

Online risk scores for pre- and postoperative prediction of early recurrence in hepatocellular carcinoma patients undergoing conversion liver resection after tyrosine kinase inhibitors and immune checkpoint inhibitors therapy.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: October 25, 2024

Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in older patients with uHCC.

Journal: Frontiers in oncology

Published: October 23, 2024

The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma -CLEAP 004 study.

Journal: Frontiers in immunology

Published: October 09, 2023

Change of indocyanine green clearance ability and liver function after transcatheter intra-arterial therapies and its impact on outcomes of resectable hepatocellular carcinoma: a retrospective cohort study.

Journal: International journal of surgery (London, England)

Published: October 06, 2023

Prognostic Values of Alpha-Fetoprotein and Des-Gamma-Carboxyprothrombin in Hepatocellular Carcinoma in China: An Analysis of 4792 Patients.

Journal: Journal of hepatocellular carcinoma

Published: April 21, 2021

Preventive effect of celecoxib in sorafenib-related hand-foot syndrome in hepatocellular carcinoma patients, a single-center, open-label, randomized, controlled clinical phase III trial.

Journal: American journal of cancer research

Published: March 13, 2020

Intention to control low central venous pressure reduced blood loss during laparoscopic hepatectomy: A double-blind randomized clinical trial.

Journal: Surgery

Published: January 09, 2020

Stereotactic Body Radiotherapy vs. Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma: A Meta-Analysis.

Journal: Frontiers in oncology

Published: December 27, 2019

Tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patients.

Journal: Cancer communications (London, England)

Published: December 19, 2019

Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Propensity Score Matching Study.

Journal: Cancers

Published: July 05, 2019

Radiofrequency ablation versus laparoscopic hepatectomy for hepatocellular carcinoma: A real world single center study.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: June 15, 2019